RP－HPLC法测定复合维生素B片中维生素B_1、B_2、B_6和烟酰胺的含量

用ＲＰ－ＨＰＬＣ法（固定相为μＢｏｎｄｐａｋ Ｃ１８柱，流动相为己烷磺酸钠冰醋酸液，紫外检测波长为２８０ｎｍ）同时测定出复合维生素Ｂ片中四个组分的含量，方法专属性强，省时；维生素Ｂ１、Ｂ２、Ｂ６和烟酰胺的平均回收率和平均相对标准偏差分别为１００．５％，２．０％；９８．０％，１．９％；１０１．８％，１．１％；１００．１％，２．１％（ｎ＝３）。     

血清白细胞介素－2受体的测定在脑血管性痴呆诊治中意义的探讨

目的 :检测脑血管性痴呆患者血清中可溶性白细胞介素 - 2 (s IL- 2 R)水平 ,评价 s IL- 2 R的测定在诊治脑血管性痴呆中的价值。方法 :采用双抗体夹心的 EL ISA法检测脑血管性痴呆患者血清中 s IL- 2 R的水平。结果 :脑血管性痴呆患者血清中的 s IL- 2 R水平较健康对照组显著增高 ,两组比较差异非常显著 (P <0 .0 1)。结论 :检测脑血管性痴呆患者血清中 s IL- 2 R水平 ,有助于了解患者的免疫功能变化及疗效观察     

应用单克隆抗体(MoAb)对白血病免疫分型的临床研究

报告了应用单克隆抗体对25例淋巴细胞白血病、5例慢性粒细胞白血病及15例急性非淋巴细胞白血病进行免疫分型并与AB分型作比较,结果提示免疫分型可以弥补FAB分型的不足,它有助于白血病临床诊断、鉴别诊断、指导治疗和判断预后。     

生长抑素受体亚型在人鼻咽癌细胞株CNE2中表达

背景与目的：生长抑素受体（somatostatin receptor SSTR）在许多肿瘤组织均有表达，为生长抑素类似物如奥曲肽用于这些肿瘤的治疗提供了生物学基础，但对生长抑素受体在鼻咽癌中表达情况的研究甚少。本研究旨在了解生长抑素受体基因在鼻咽癌细胞中的表达情况，为生长抑素类似物用于鼻咽癌治疗的进一步研究提供试验基础。方法：采用RT—PCR法和SP免疫组化法联合检测体外培养的人鼻咽癌细胞株CNE2的SSTRs表达，并对PCR mRNA产物测序以鉴定结果。结果：RT—PCR提示人鼻咽癌细胞株CNE2分别表达生长抑素受体亚型SSTR1、SSTR2、SSTR4；免疫组化结果：人鼻咽癌细胞株CNE2表达SSTR1、SSTR2A为强阳性（〉60％），表达SSTR4为弱阳性、SSTR2介于两者之间、SSTR3和SSTR5则无表达。结论：我们的研究证实人鼻咽癌细胞株CNE2有多种生长抑素受体亚型基因表达，且以表达SSTR1、SSTR2较多。     

PPARδ基因多态与有氧能力及训练敏感性的关联研究

目的探讨过氧化物酶体增殖物激活受体δ(PPARδ)基因第四外显子的单核苷酸多态(C294T)是否与有氧运动能力及训练敏感性相关联。方法对102名中国北方地区汉族男性青年进行为期18周的耐力训练(每次5000米、每周3次)。强度以个体通气无氧阈(VT)对应的心率(HRVT)为标准,前10周采用95%通气无氧阈对应的心率(HRVT±3),后8周采用105%通气无氧阈对应的心率(HRVT±3)。递增负荷运动实验测定受试者训练前后VO2max及相关指标和跑节省化时的心率(HR)、通气量(VE)和摄氧量(VO2)。采用限制性片断长度多态(PCR-RFLP)法测定PPARδ基因C294T位点。结果三种基因型的分布频率分别为CC基因型9人(0.09)、CT基因型37人(0.36)和TT基因型56人(0.55),符合Hardy-Weinberg平衡。按基因型分组后,CC基因型训练前的VO2max相对值显著性高于CT基因型和TT基因型(P<0.05);携带不同基因型群体的VO2max、跑节省化测试中的各项指标的变化率无显著性差异(P>0.05)。结论PPARδ基因第四外显子的单核苷酸C294T多态与VO2max相对值的初始值相关联,但与有氧耐力训练效果不关联。     

心肌缺血预适应中的离子通道

缺血预适应调动机体内源性抗损伤能力，保护缺血缺氧的组织细胞，是近年来心血管领域研究的热点之一。本该对心肌缺血预适应中的离子通道、三磷酸腺苷敏感性钾通道（KATP通道）、L-型钙道道（L-Ca^2 通道）、体积调节性氯通道（Cl vol通道）的特性、作用及其机制作一综述。     

大鼠全脑缺血再灌注损伤后调控基因Bcl-2、Bax的表达及与细胞凋亡的关系

目的:本研究旨在探讨Bcl-2及Bax蛋白在大鼠全脑缺血再灌注损伤中的变化及与细胞凋亡的关系。方法:雄性Wistar大鼠56只,随机分为假手术组、缺血15分钟再灌注1、6、12、24、48、72小时组。采用大鼠四条血管阻断方法制备大鼠全脑缺血再灌注模型。采用TUNEL法观察不同再灌注时间组海马CAl区细胞凋亡的变化。采用免疫组化法观察Bcl-2及Bax蛋白表达水平的变化。结果:脑缺血损伤后随再灌注时间延长凋亡细胞逐渐增多,至再灌注48小时达到高峰,72小时后减少。Bcl-2表达至再灌注12小时达高峰,再灌注24~72小时组逐渐减弱。Bax表达至48小时达高峰,再灌注72小时减少。结论:Bcl-2于再灌注早期表达增强,Bax于再灌注中期表达增强,Bcl-2/Bax比例失衡可能是大鼠全脑缺血再灌注后神经细胞凋亡的机制之一。     

老年2型糖尿病患者骨密度及临床相关因素分析

目的 了解老年2型糖尿病患者骨密度的变化，初步探讨临床相关因素对骨密度变化的影响。方法 采用双能X线骨密度仪测定65例老年2型糖尿病患者及80例年龄、性别匹配的正常对照者腰椎及髋部骨密度，同时测定前者空腹血糖（FBG）、餐后2h血糖（PBG）、空腹C肽、餐后2hC肽、果糖胺（FA）、糖化血红蛋白（HBAle）、胆固醇（chol）、甘油三酯（TG）。结果 65例糖尿病患者各部位骨密度值均低于正常对照者，但仅腰椎降低有统计学意义（P〈0．05）；糖尿病组30例（45％）合并骨质疏松（OP）。OP与非0P组病程有显著性差异（P〈0．05）。结论 2型糖尿病会导致骨矿密度减低，并与糖尿病病程密切相关。     

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week,randomized, double‐blind,parallel‐group study

Aim: The aim of the current study was to assess the efficacy, safety, and tolerability of lumiracoxib 200 mg once daily (o.d.) in relieving osteoarthritis (OA) knee pain in patients in China, Taiwan, and South Korea. Methods: Patients of either sex (aged ≥ 18 years) with symptomatic, primary OA of the knee for ≥ 3 months were eligible for inclusion if they had OA pain intensity of ≥ 40 mm (100 mm visual analogue scale [VAS]) in the target knee joint during the previous 24 h. Patients were required to undergo regular non‐steroidal anti‐inflammatory drug therapy for ≥ 6 weeks. After 3–7 days of screening, patients were randomized (1 : 1) to receive either lumiracoxib 200 mg o.d. or celecoxib 200 mg o.d. The primary efficacy comparison between the study groups was overall OA pain intensity (VAS) in the target knee after 6 weeks of treatment. Results: The mean overall OA pain intensity (VAS) in the target knee after 6 weeks decreased from 60.6 mm to 35.7 mm and 60.5 mm to 36.1 mm in the lumiracoxib and celecoxib groups, respectively. Both study groups showed similar results in terms of improvement in both patient's and physician's global assessment of disease activity and functional health status. The percentage of adverse events (AEs) in the lumiracoxib and celecoxib groups (40.3% and 37.9%, respectively) was similar, as was the proportion of treatment‐related AEs (21.0% and 18.2%, respectively). Conclusions: Lumiracoxib 200 mg o.d. provided effective and well‐tolerated pain relief similar to that achieved with celecoxib 200 mg o.d. in knee OA patients.     

Robust fixed‐order H2 controller for micro air vehicle—design and validation

Design and real‐time validation of a robust fixed‐order H₂ optimal controller for micro aerial vehicle, named Sarika‐2, is presented. Strengthened discrete optimal projection equations, which approximate the first‐order necessary optimality condition, are used for the controller design. Effect of low‐frequency gust disturbance and high‐frequency sensor noise is alleviated through the output sensitivity and control sensitivity minimization. The novelty of this paper is that a single robust H₂ controller, which is designed at the central operating point, ensures simultaneous stabilization of the radio‐controlled aircraft over the entire cruise speed range of 16–26 m/s. The controller is implemented on a digital‐signal‐processor‐based flight computer, and subsequently, it is validated through the real‐time hardware‐in‐loop‐simulation. The responses obtained from the hardware‐in‐loop‐simulation compares well with those obtained from the off‐line simulation. Copyright © 2006 John Wiley & Sons, Ltd.